Blog

Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under investigation for its potential in treating various cancersWhat is the mechanism of action for Tiragolumab?Tiragolumab blocks TIGIT, a receptor on immune cells that inhibits anti-tumor activity, restoring the immune system's ability to attack cancer cells.What cancers does Tiragolumab target? Tiragolumab is being studied in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and other solid tumors, often in combination with atezolizumab.What cancers does Tiragolumab target? Pr …

Quick Facts About RituximabWhat is Rituximab?Rituximab is a monoclonal antibody targeting CD20, a protein found on the surface of B cells. It plays a crucial role in treating autoimmune diseases and certain cancers, such as non-Hodgkin's lymphoma.What is the mechanism of action for Rituximab?Rituximab works by binding to CD20, leading to B cell destruction through immune-mediated processes such as complement activation and apoptosis.What are the clinical applications of Rituximab?Rituximab is used to treat conditions like rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma. It’s also being explored for multiple sclerosis (MS) and lupus.What are the cl …

Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune responses.What is the mechanism of action for Tesnatilimab?Tesnatilimab binds to the CD47 receptor on cancer cells, enhancing their phagocytosis by macrophages and other immune cells.What are the clinical applications of Tesnatilimab?It is being explored for its efficacy in treating various cancers, including hematologic malignancies and solid tumors.Is Tesnatilimab safe?Studies highlight its potential with a manageable safety profile, though some patients may experience mild-to-moderate immune-relat …